Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AbbVie
Biotech
AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer
AbbVie is paying $700 million for a next-generation rival to J&J's Tecvayli, positioning the Big Pharma to advance a new option for multiple myeloma.
Nick Paul Taylor
Jul 10, 2025 9:01am
AbbVie inks $2.1B Capstan buyout to enter in vivo CAR-T market
Jun 30, 2025 9:45am
AbbVie taps oncology research org for aid running diverse trials
May 28, 2025 11:25am
AbbVie tosses ADARx $335M for siRNA options deal
May 14, 2025 9:00am
M&A remains ‘top priority’ for pharmas in face of tariff threat
Apr 25, 2025 10:41am
German program matches lost NIH grants with pharma funders
Apr 7, 2025 10:50am
